The Market Reports

Synopsis
The global market for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 2022 million by 2031 with a CAGR of -1.6% during the forecast period 2025-2031.
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
The market for Chemotherapy Induced Nausea and Vomiting (CINV) drugs is primarily driven by the rising global cancer burden and the growing use of aggressive chemotherapy regimens. As cancer treatments become more potent, side effects like nausea and vomiting become more frequent and severe, increasing the demand for effective antiemetic therapies. The availability of combination antiemetic drugs, such as NK1 receptor antagonists, 5-HT3 antagonists, and corticosteroids, has significantly improved patient outcomes and quality of life. Furthermore, increasing awareness among patients and oncologists about the importance of supportive care is encouraging the adoption of CINV drugs in both inpatient and outpatient settings.
Despite the growth potential, the CINV drugs market faces several challenges. One of the primary hurdles is the high cost of novel antiemetic therapies, which limits access in low- and middle-income countries. Generic competition is also impacting the revenues of branded products. Additionally, not all patients respond equally to antiemetic drugs, and some experience breakthrough or refractory nausea despite prophylactic treatment. These clinical limitations highlight the need for personalized therapy, but variability in patient responses makes it difficult to standardize treatment protocols. Regulatory hurdles and slow drug approval timelines further restrain market expansion.
A key trend in the CINV drugs market is the development of long-acting and combination therapies that improve adherence and efficacy. Innovations like extended-release formulations and transdermal delivery systems are gaining popularity for their convenience and effectiveness. There's also a growing focus on integrating CINV drugs into broader oncology care programs, including palliative and home-based care. Pharmaceutical companies are investing in clinical trials to expand the indications of existing antiemetics and explore novel targets such as cannabinoid receptors. As cancer care becomes more patient-centric, the demand for well-tolerated and accessible CINV treatments is expected to grow steadily.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top five manufacturers hold a share over 26%.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs by region & country, by Type, and by Application.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Chemotherapy Induced Nausea and Vomiting (CINV) Drugs cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Nausea and Vomiting (CINV) Drugs.
Market Segmentation
By Company
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Viatris
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index